Physical Inactivity and Sleep Inefficiency Accentuate the Genetic Risk of Obesity

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 23-OR
Author(s):  
ANDREW R. WOOD ◽  
SAMUEL E. JONES ◽  
REBECCA RICHMOND ◽  
SHAFQAT AHMAD ◽  
HANIEH YAGHOOTKAR ◽  
...  
2018 ◽  
Vol 42 (4) ◽  
pp. 354-365 ◽  
Author(s):  
Jihye Kim ◽  
Peter Kraft ◽  
Kaitlin A. Hagan ◽  
Laura B. Harrington ◽  
Sara Lindstroem ◽  
...  

2009 ◽  
Author(s):  
Ariel L. Del Gaizo ◽  
Robert D. Dvorak ◽  
Ryan M. Engdahl ◽  
Christina J. Eliason

2010 ◽  
Vol 48 (08) ◽  
Author(s):  
V Zimmer ◽  
F Mihalache ◽  
A Höblinger ◽  
F Grünhage ◽  
M Krawczyk ◽  
...  

1998 ◽  
Vol 80 (09) ◽  
pp. 372-375 ◽  
Author(s):  
Hidemi Yoshida ◽  
Tadaatsu Imaizumi ◽  
Koji Fujimoto ◽  
Hiroyuki Itaya ◽  
Makoto Hiramoto ◽  
...  

SummaryPlatelet-activating factor (PAF) acetylhydrolase is an enzyme that inactivates PAF. Deficiency of this enzyme is caused by a missense mutation in the gene. We previously found a higher prevalence of this mutation in patients with ischemic stroke. This fact suggests that the mutation might enhance the risk for stroke through its association with hypertension. We have addressed this hypothesis by analyzing the prevalence of the mutation in hypertension. We studied 138 patients with essential hypertension, 99 patients with brain hemorrhage, and 270 healthy controls. Genomic DNA was analyzed for the mutant allele by the polymerase-chain reaction. The prevalence of the mutation was 29.3% (27.4% heterozygotes and 1.9% homozygotes) in controls and 36.2% in hypertensives and the difference was not significant. The prevalence in patients with brain hemorrhage was significantly higher than the control: 32.6% heterozygotes and 6.1% homozygotes (p <0.05). PAF acetylhydrolase deficiency may be a genetic risk factor for vascular diseases.


Sign in / Sign up

Export Citation Format

Share Document